Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Context/Objective: Approximately 15% of thyroid cancer patients develop subsequent metastases. The clinical course of patients with metastatic thyroid carcinoma is highly variable. We hypothesized that the metabolic activity of metastatic lesions, as defined by retention of 2-[18F]fluoro-2-deoxyglucose (FDG), would correlate with prognosis. Design/Patients: The initial FDG-positron emission tomography (PET) scans from 400 thyroid cancer patients were retrospectively reviewed and compared with overall survival (median follow-up, 7.9 yr). We examined the prognostic value of clinical information such as gender, age, serum thyroglobulin, American Joint Committee on Cancer (AJCC) stage, histology, radioiodine avidity, FDG-PET positivity, number of FDG-avid lesions, and the glycolytic rate of the most active lesion. Results: Age, initial stage, histology, thyroglobulin, radioiodine uptake, and PET outcomes all correlated with survival by univariate analysis. However, only age and PET results continued to be strong predictors of survival under multivariate analysis. The initial American Joint Committee on Cancer stage was not a significant predictor of survival by multivariate analysis. There were significant inverse relationships between survival and both the glycolytic rate of the most active lesion and the number of FDG-avid lesions. Conclusions: FDG-PET scanning is a simple, expensive, but powerful means to restage thyroid cancer patients who develop subsequent metastases, assigning them to groups that are either at low (FDG negative) or high (FDG positive) risk of cancer-associated mortality. We propose that the aggressiveness of therapy for metastases should match the FDG-PET status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HAY, I. D., Bergstralh, E. J., Goellner, J. R., Ebersold, J. R., & Grant, C. S. (1993) · PubMed · Cited by 1,344
Edwards, B. K., Brown, M. L., Wingo, P. A., Howe, H. L., Ward, E., Ries, L. A. G., Schrag, D., Jamison, P. M., Jemal, A., Wu, X. C., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji289 · Cited by 952
An expanded view of risk-group definition in differentiated thyroid carcinoma.
Cady, B., & Rossi, R. (1988) · PubMed · Cited by 937
Hay, I. D. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30310-4 · Cited by 634
MARTIN, S., MAURICE, T., VATHAIRE, F. D., CATHERINE, H., GARDET, P., TRAVAGLI, J.-P., FRAGU, P., LUMBROSO, J., CAILLOU, B., & PARMENTIER, C. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-4-960 · Cited by 552
Schlumberger, M. J., Vathaire, C. C.-D., de Vathaire, F., Travagli, J. P., Gardet, P., Lumbroso, J., Francese, C., Fontaine, F., Ricard, M., & Parmentier, C. (1996) · PubMed · Cited by 545
National Thyroid Cancer Treatment Cooperative Study Registr Group, Sherman, S. I., Brierley, J. D., Sperling, M., Ain, K. B., Bigos, S. T., Cooper, D. S., Haugen, B. R., Ho, M., Klein, I., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9 · Cited by 402
Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
Feine, U., Lietzenmayer, R., Hanke, J. P., Held, J., Wöhrle, H., & Müller-Schauenburg, W. (1996) · PubMed · Cited by 390
RUEGEMER, J. J., HAY, I. D., BERGSTRALH, E. J., RYAN, J. J., OFFORD, K. P., & GORMAN, C. A. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-501 · Cited by 389
Wang, W. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.3.1107 · Cited by 339
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
“A study (378) that retrospectively examined the clinical course of 400 thyroid cancer patients with distant metastases who had undergone (18)FDG-PET scanning found that although age, initial tumor stage, histology, Tg level, RAI uptake, and PET outcomes all correlated with survival by univariate analysis, only age and…”
Self-citationDurante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,675
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz400 · Cited by 1,200
Tuttle, R. M., Tala, H., Shah, J., Leboeuf, R., Ghossein, R., Gonen, M., Brokhin, M., Omry, G., Fagin, J. A., & Shaha, A. (2010) · Thyroid · doi:10.1089/thy.2010.0178 · Cited by 924
Self-citationSelumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Self-citationFass, L. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.04.001 · Cited by 822
Guidelines for radioiodine therapy of differentiated thyroid cancer
Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 727
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Self-citationPhase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Progress in molecular-based management of differentiated thyroid cancer
Xing, M., Haugen, B. R., & Schlumberger, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60109-9 · Cited by 573
Patel, K. N., Yip, L., Lubitz, C. C., Grubbs, E. G., Miller, B. S., Shen, W., Angelos, P., Chen, H., Doherty, G. M., Fahey, T. J., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003580 · Cited by 541
Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y. (2014) · Journal of Thyroid Research · doi:10.1155/2014/638747 · Cited by 475
Carr, L. L., Mankoff, D. A., Goulart, B. H., Eaton, K. D., Capell, P. T., Kell, E. M., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 422
Definition and management of radioactive iodine-refractory differentiated thyroid cancer
Schlumberger, M., Brose, M., Elisei, R., Leboulleux, S., Luster, M., Pitoia, F., & Pacini, F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70215-8 · Cited by 377
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pacini, F., Castagna, M. G., Brilli, L., & Pentheroudakis, G. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq190 · Cited by 350
Current practice in patients with differentiated thyroid cancer
Schlumberger, M., & Leboulleux, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00448-z · Cited by 342
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pacini, F., Castagna, M. G., Brilli, L., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds230 · Cited by 290
Fugazzola, L., Elisei, R., Fuhrer, D., Jarzab, B., Leboulleux, S., Newbold, K., & Smit, J. (2019) · European Thyroid Journal · doi:10.1159/000502229 · Cited by 285
Laure Giraudet, A., Al Ghulzan, A., Aupérin, A., Leboulleux, S., Chehboun, A., Troalen, F., Dromain, C., Lumbroso, J., Baudin, E., & Schlumberger, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0667 · Cited by 272
Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels
Giraudet, A. L., Vanel, D., Leboulleux, S., Aupérin, A., Dromain, C., Chami, L., Ny Tovo, N., Lumbroso, J., Lassau, N., Bonniaud, G., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1211 · Cited by 265
Sheng, S. L., Liu, J. J., Dai, Y. H., Sun, X. G., Xiong, X. P., & Huang, G. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08748.x · Cited by 263
Bone metastases from differentiated thyroid carcinoma
Muresan, M. M., Olivier, P., Leclere, J., Sirveaux, F., Brunaud, L., Klein, M., Zarnegar, R., & Weryha, G. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0229 · Cited by 260
PET/CT imaging in cancer: current applications and future directions
Farwell, M. D., Pryma, D. A., & Mankoff, D. A. (2014) · Cancer · doi:10.1002/cncr.28860 · Cited by 230
Differentiated Thyroid Cancer—Treatment: State of the Art
Schmidbauer, B., Menhart, K., Hellwig, D., & Grosse, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061292 · Cited by 205
A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer
Pennell, N. A., Daniels, G. H., Haddad, R. I., Ross, D. S., Evans, T., Wirth, L. J., Fidias, P. H., Temel, J. S., Gurubhagavatula, S., Heist, R. S., et al. (2008) · Thyroid · doi:10.1089/thy.2007.0120 · Cited by 197
Luster, M., Aktolun, C., Amendoeira, I., Barczyński, M., Bible, K. C., Duntas, L. H., Elisei, R., Handkiewicz-Junak, D., Hoffmann, M., Jarząb, B., et al. (2019) · Thyroid · doi:10.1089/thy.2017.0129 · Cited by 181
“For one, the text might suggest Tg rate of change in well differentiated tumors, for example doubling time (121–124), or fluorodeoxyglucose avidity (125,126) as potentially useful prognostic indicators.”
Self-citationDeandreis, D., Al Ghuzlan, A., Leboulleux, S., Lacroix, L., Garsi, J. P., Talbot, M., Lumbroso, J., Baudin, E., Caillou, B., Bidart, J. M., et al. (2011) · Endocrine Related Cancer · doi:10.1677/erc-10-0233 · Cited by 177
“…(after rhTSH injections or after L-T4 withdrawal) or during L-T4 treatment, but this did not change the metastatic and metabolic status (FDGC/FDGK) of our patients and it did not influence the prognostic value of FDG uptake itself, in accordance with a previous study (Robbins et al. 2006).”
BackgroundResultInfluentialRomei, C., Ciampi, R., Faviana, P., Agate, L., Molinaro, E., Bottici, V., Basolo, F., Miccoli, P., Pacini, F., Pinchera, A., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0130 · Cited by 160
New therapeutic approaches for metastatic thyroid carcinoma
Baudin, E., & Schlumberger, M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70034-7 · Cited by 143
Shonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., et al. (2022) · Head & Neck · doi:10.1002/hed.27025 · Cited by 117
Self-citationCell hierarchy, metabolic flexibility and systems approaches to cancer treatment
M. Herst, P., & V. Berridge, M. (2013) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201011314030005 · Cited by 16
Metadata
- Authors
- Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gonen, M., Strauss, H. W., Tuttle, R. M., Drucker, W., & Larson, S. M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-02-01
- Volume
- 91
- Issue
- 2
- Pages
- 498-505
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2079353352
- Cited by
- 587
- References
- 25
- FWCI
- 19.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.